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Both activated protein C (APC) resistance and protein C de-
ficiency are associated with an increased risk for venous
thrombosis. To assess their tendencies to venous thrombo-
sis, we compared the median age of first venous thrombo-
embolism in patients with factor V Leiden or protein C defi-
ciency, who were identified either within unselected
consecutive cases with a first deep venous thrombosis de-
rived from a population-based case-control study, or identi-
fied by selection of patients with a deep venous thrombosis,
who were referred for thrombophilia work-up. The median
age of onset for 92 unselected APC resistant cases was 43
years and for 13 unselected protein C-deficient cases 47
years. The median age at the first thrombotic event for 28
APC-resistant members of thrombophilia families was 29
years and for 50 protein C-deficient members of thrombo-
PROTEIN C is an important mhibitor of the clotting sys-tem that mactivates the coagulation cofactors Va and
Villa' In familial resistance to activated protein C (APC
resistance) and m protein C deficiency, factor Va is not
properly mactivated by APC APC resistance is associated
with a Imitation m the factor V gene, which predicts the
synthesis of an abnormal factor V molecule (FV Leiden)2 4
In protein C deficiency, the occurrence of thrombosis is di-
rectly related to the reduced level of functional protein C
Heterozygotes of factor V Leiden or protein C deficiency
have a 5- to 10-fold increased nsk of venous thrombosis 5 f >
APC resistance has the highest prevalence of the throm-
bophilia disorders (20% of unselected thromboembolic pa-
tients, 50% of mdividuals with thrombophilia, and 3% to
5% of healthy mdividuals)25 Therefore, the clinical manage-
ment (le, treatment and prophylactic measures for patients
with protein C deficiency or factor V Leiden and their rela-
tives) will affect many mdividuals Even though specific
studies into the management of APC resistance are presently
unavailable, climcians seek optimal care for their patients
A first approach might be to adopt a similar policy äs for
protein C deficiency This may be valid, unless APC resis-
tance has a different clinical presentation, for instance a less
pronounced thrombotic risk, äs has been suggested 7
To obtam a first assessment of the thrombotic tendency in
APC-resistant mdividuals, we compared protein C—deficient
patients and APC-resistant patients with regard to the age at
which the first thrombotic event occurred We hypothesized
that selection of patients will play an important role To
assess this role of selection in the presentation of the first
thrombotic event (le, deep venous thrombosis), we compared
a senes of unselected consecutive patients from a population-
based case-control study with a group of selected patients
who had been referred for hitherto unexplamed familial
thrombophilia
MATERIALS AND METHODS
The first group of patients (unselected patients) was denved from
a population based case control study on venous thrombosis, the
Leiden Thrombophilia Study (LETS) ΐ6 These cases were 471 con
secutive patients younger than 70 years, with a first, objectively
confirmed episode of deep vem thrombosis and free of underlymg
philia families 31.5 years. The median age of onset for all
unselected patients (n = 105) was 45 years of age (ränge,
16 to 69 years) and the median age of onset for all selected
patients from the thrombophilia families (n = 78) was 30.5
years (ränge, 16 to 67 years) These results show that within
the case-control study and the family studies, the median
age of onset is very similar in patients with APC resistance
and patients with protein C deficiency This suggests that
APC resistance is not less severe with respect to risk of
thrombosis than (heterozygous) protein C deficiency. In con-
clusion, the median age at which the first thrombosis occurs
mainly depends on the way the patients are identified and
not on the type of thrombophilia
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mahgnancy APC resistance was detected (presence of factor V
Leiden) in 92 cases (84 heterozygotes and eight homozygotes) Pro-
tein C deficiency, confirmed by the Identification of a protein C gene
mutation, was detected in 13 cases (all heterozygotes) None of the
cases camed both gene defects, so there were 366 noncamers
The second group of patients (selected patients) originales from
two large panels of patients with a first deep venous thrombosis,
recruited from patients who were referred to our center for diagnosüc
work up for venous thrombophilia These were patients with a posi-
tive family history of thrombosis and patients who had expenenced
a thrombotic event before the age of 40 years m the absence of
precipitating condiüons The first panel, collected by Engesser et
al,8 consisted of 113 probandi In several of these probandi, muta
tions leadmg to protein C deficiency (and protein S deficiency, anü-
thrombm deficiency) and later APC resistance were identified From
this panel, 12 APC resistant probandi were randomly selected, and
of these probandi, we tested 88 family members for the presence of
factor V Leiden 9 The second panel, collected by Allaart et al,9
consisted of 80 protein C-deficient probandi From this panel, 24
protein C—deficient probandi were randomly selected, and of these
probandi, we tested 153 family members for the presence of the
protein C gene mutation private to a particular family9 In the fami-
lies of these 36 APC-resistant or protein C-deficient probandi, we
mvestigated siblmgs, children, and parents of the proband plus sib
hngs of the affected parent of the proband Family members over
70 years of age and family members with underlymg mahgnancy
were excluded for practical purposes
For the two groups unselected, consecutive patients with factor
V Leiden or protein C deficiency from a population-based case
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Fig 1. Age at first venous thrombotic event of all unselected (LETS) cases and of patients from 36 selected thrombophilia families. The horizontal
lines represent the median ages of onset. The bold horizontal lines represent the median ages of onset of the probandi and their relatives together
in families with APC resistance or protein C deficiency. For the protein C deficiency families, the median age of onset was calculated without the
seven probandi and relatives who carried both defects. (A) LETS cases, APC-resistant (n = 92). (Θ), homozygous; (·), heterozygous. (B) LETS cases,
Protein C (PC)-deficient (n = 131. (C) LETS cases, noncarriers (n = 366). (D) APC-resistant families, APC resistant relatives (n = 28). (O), proband.
(E) PC-deficient families, PC-deficient relatives (n = 57). (O), proband; (®), APC-resistant and PC-deficient proband; (β), PC-deficient relative; (Θ),
APC-resistant and PC-deficient relative. (F) APC resistance and PC deficiency families, noncarriers (n = 9).
control study, and selected patients from thrombophilia families with
hereditary APC resistance or protein C deficiency, we calculated the
median age at the first venous thrombotic event. The median ages
in the different groups were compared by the Mann-Whitney U lest.
With the terms unselected and selected, we wish to emphasize the
difference in identification mechanisms. In the first group (unselected
consecutive cases, not referred for thrombophilia work-up), the ifi-
cluding criteria were not so stringent äs in the thrombophilia group
(the selected group including probandi who were referred for throm-
bophilia work-up and their family members who experienced a first
deep venous thrombosis) and specifically not aimed at detecting
hereditary cases.
Our analysis did not concern pulmonary embolism or superficial
thrombophlebitis. In the thrombophilia families, äs well äs in the
case-control study, we included only the thrombotic events, which
were diagnosed objectively.
RESULTS
The median age at the first thrombotic event for the 92
cases with factor V Leiden from the population-based case-
control study was 43 years (ränge, 16 to 69 years; median
age eight homozygotes: 32.5 years, ränge, 22 to 56 years)
(Fig 1). For the 13 cases with protein C deficiency in this
study, the median age at the first thrombotic event was 47
years (ränge, 19 to 63 years). For the 366 noncarriers, the
median age at the first thrombosis was 45.5 years (ränge, 15
to 69 years).
In the 12 thrombophilia families with APC resistance,
factor V Leiden was detected in 48 of the 88 relatives (all
heterozygotes, probandi excluded). Venous thrombotic
events had occurred in 16 carriers and in four of the 40
noncarriers. There were no carriers of both APC resistance
and protein C deficiency.
For the 12 probandi in thrombophilia families with APC
resistance, the median age at the first thrombosis was 29.5
years (ränge, 21 to 46 years). For their 16 APC-resistant
relatives, the median age at the first thrombosis was 29 years
(ränge, 16 to 63 years). The median age of onset of the
probandi and their relatives together was 29 years (ränge,
16 to 63 years). The median age of onset for the four noncar-
riers was 33.5 years (ränge, 26 to 54 years).
In the 24 thrombophilia families with protein C deficiency,
protein C deficiency alone was detected in 66 of the 153
l
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Fig 2 Box plot of age at first thrombosis according to defect in
the four main groups It shows the eldest and youngest observed
age of onset (horizontal lines at the end of the boxes), and the median
age of onset (horizontal line inside the boxes) The Iower and upper
boundanes are the 25th and 75th percentiles, their difference corre
sponds to the mterquartile ränge and the length of each box Fifty
percent of the cases of each group have values within the box
relatives (all heterozygous, probandi excluded), and 29 of
these camers had expenenced a venous thrombotic event
Both APC resistance and protem C deficiency were detected
m three probandi and nme relatives (four of them had expen
enced venous thrombosis) Factor V Leiden alone was de-
tected in seven relatives, and two of them had expenenced
venous thrombosis Venous thrombosis did occur m five of
the 71 noncamers
The median age at first thrombosis for the 21 probandi m
thrombophilia famihes with protem C deficiency was 26
years (ränge, 16 to 50 years) For their 29 protem C-defi
cient relatives, the median age at first thrombosis was 35
years (ränge, 17 to 67 years) The median age of onset of
the probandi and their relatives together was 315 years
(ränge, 16 to 67 years) For the three probandi who carned
both defects, the median age of onset was 21 years (ränge
20 to 29 years), and the median age of onset of the four
relatives who camed both defects was 30 years (ränge, 19
to 55 years) The age of onset of the two relatives with factor
V Leiden alone was 25 years (ränge, 29 to 41 years, not
mentioned in Fig 1) The median age of onset for the five
noncarriers was 33 years (ränge, 21 to 57 years)
When we compare (Fig 2) all unselected APC resistant
and protem C-deficient cases from the case-control study
(n = 97) with all selected APC resistant and piotein C-
deficient patients from the thrombophilia families (n = 78,
excluding homozygous patients and patients with both gene
defects), the median age at the first thrombosis for all unse
lected patients was 45 years (ränge, 16 to 69 years) and the
median age at the first thrombosis for all (selected) patients
from the thrombophilia famihes was 30 5 years (ränge, 16
to 67 years, P < 001)
DISCUSSION
We compared patients with APC resistance and protem
C deficiency, who were identified either from consecutive
patients with a fiist deep venous thrombosis (unselected), or
identified from patients with a first deep venous thrombosis
who were leferred for thrombophilia work-up and their fam
ily members who had expenenced a deep venous thrombosis
(selected)
We found that the median age at which the first thrombosis
occuned only depended on the way the patients were identi-
fied and not on the type of gene defect The first thrombotic
event occurred earlier in hfe in (selected) symptomatic rela
tives of APC-resistant or protem C-deficient probandi than
in unselected APC-resistant or protem C-deficient cases
from the case-control study (P < 001 for APC resistance
and P = 025 for protem C deficiency)
Withm each group (selected and unselected patients) the
median age of onset in patients with APC resistance and
patients with protem C deficiency was very similar (Fig 2)
These findmgs do not support a difference m seventy, with
regard to thrombotic tendency, between APC resistance and
heterozygous protem C deficiency The fact that the selection
of the thrombophilia famihes shows a Iower mean age of
first thrombotic event than the group of unselected patients,
may be based on comcidence, le, selection of those in the
Iower ränge of the distnbution of ages of onset As pomted
out by Majerus,10 it seems likely that these individuals also
carry other genetic or environmental nsk factors, which will
determme individual risk lo Because there is no reason to
assume that these factors are more often present m combina
tion with protem C deficiency than with APC resistance, or
vice versa, we conclude that protem C deficiency and APC
resistance contribute to about an equal extent to the risk of
thrombosis This risk may be further enhanced by other fac-
tors, äs has been shown previously (Koeleman et al," Van
denbroucke et aln), and those with the most unfavorable
nsk profile of known or unknown causes, will be identified
through stnngent selection " l2
In accordance with previous reports (Koeleman et al,"
Gandrille et al,n and Zoller et al14) and according to the
previous remark carnership of two defects does lead to an
increased thrombotic tendency, äs mamfested m the striking
young median age in the probandi of the protem C-deficient
famihes who carned both defects (21 years, ränge, 20 to 29
years) " n 14 The fact that the median age at first thrombosis
in referred thrombophilia famihes is Iower than the median
age at first thrombosis in unselected cases, appears to be the
result of selection These results cannot rule out the possibil-
ity of differences in thrombotic tendency between types of
thrombophilia We show here, however, that these differ-
ences will be only minor compared with the effect of differ-
ences in the mode of selection of patients The absence of
much difference in thrombotic tendency in protem C defi
ciency and APC resistance is also in accordance with the
results of the LETS-study, where uniform selection cnteria
were applied the relative nsk for protem C deficiency (6 5)
was very similar to that for APC resistance (6 6)5 6
The results in the group of thrombophilia famihes were
obtamed under stnngent selection cnteria APC resistance,
has a much (about 10 fold) higher frequency than protem C
deficiency Chnicians in actual practice will diagnose APC
resistance easier than protem C deficiency, and the age of
onset in these patients probably will approximate the median
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age of onset in the group of unselected cases. Because protein
C deficiency is so rare, most protein C-deficient patients
will be identified in referred families, and the age of onset
in these patients will approximate the median age of onset
in the group of selected patients from the group of throm-
bophilia families.
We conclude that the overall thrombotic risk is similar in
protein C deficiency and APC resistance. Major differences
are found, however, between selected individuals, ie, those
referred for thrombophilia work-up, and unselected individu-
als, ie, consecutive patients with venous thrombosis. There-
fore, there is no reason to differentiate in clinical manage-
ment by type of thrombophilia, whereas it may prove
beneficial to take the way an individual was identified into
account in customizing individualized care.
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